Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208541 | 0.82 | SRD5A2 (0.32) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4060990 | 0.82 | SRD5A2 (0.32) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4191602 | 0.81 | XDH (0.35) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL207570 | 0.78 | MAP2K4 (0.35) | — | |
| SCHEMBL1092228 | 0.77 | PDE4A (0.33) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1094081 | 0.77 | PDE4A (0.33) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2993023 | 0.73 | PDE4D (0.37) | ADRB1ADRB3 | |
| SCHEMBL208946 | 0.73 | P2RX7 (0.38) | MEN1KMT2A | |
| SCHEMBL1093033 | 0.72 | PSD (0.34) | — | |
| SCHEMBL3544149 | 0.72 | KDM4E (0.37) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088776-B2 | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | XDH 950/4885PRKAB2 1822/4885PRKAG1 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.